| 2026-03-23 Filed 2026-03-23 | Baranick Brian Officer: EVP, GM, Precision Oncology | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 33,321 | 0 | — | 137,195 | Direct (D) | No | F1, F2 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
- F2 At the effective time of the Merger (the Effective Time), each performance based restricted stock unit (PSU) outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the Merger Consideration) in respect of each share of the Issuer's common stock, par value $0.01 per share (Common Stock) subject to such PSU, less any applicable tax withholding.
| Open filing 0001193125-26-118765 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Baranick Brian Officer: EVP, GM, Precision Oncology | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 137,195 | — | — | 0 | Direct (D) | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118765 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Baranick Brian Officer: EVP, GM, Precision Oncology | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 795 | — | — | 0 | Indirect (I) Held in 401(k) Plan | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118765 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Baranick Brian Officer: EVP, GM, Precision Oncology | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Restricted Stock Units — underlying Common Stock (28,063) | Disposed (D) | 28,063 | — | — | 0 | Direct (D) | No | F4, F6, F5 - F4 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
- F6 At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
- F5 These RSUs vest in four equal annual installments beginning on February 25, 2027.
| Open filing 0001193125-26-118765 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | COWARD D SCOTT Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 52,164 | — | — | 5,398 | Direct (D) | No | F1 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
| Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | COWARD D SCOTT Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 5,398 | — | — | 0 | Direct (D) | No | F2 - F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
| Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | COWARD D SCOTT Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 4,694 | — | — | 0 | Indirect (I) Held in 401(k) Plan | No | F1 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
| Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | COWARD D SCOTT Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (4,175) — exercise price 44.37 | Disposed (D) | 4,175 | — | — | 0 | Direct (D) | No | F4, F3 - F4 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F3 These options became exercisable on February 27, 2022.
| Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | COWARD D SCOTT Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (10,786) — exercise price 92.62 | Disposed (D) | 10,786 | — | — | 0 | Direct (D) | No | F4, F5 - F4 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F5 These options became exercisable on February 26, 2023.
| Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | COWARD D SCOTT Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (12,875) — exercise price 98.18 | Disposed (D) | 12,875 | — | — | 0 | Direct (D) | No | F4, F6 - F4 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F6 These options became exercisable on February 14, 2024.
| Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Trigg Leslie Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 3,244 | — | — | 13,925 | Direct (D) | No | F1 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
| Open filing 0001193125-26-118740 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Trigg Leslie Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 13,925 | — | — | 0 | Direct (D) | No | F2 - F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
| Open filing 0001193125-26-118740 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Herriott James Officer: SVP, General Counsel Sec | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 68,195 | — | — | 0 | Direct (D) | No | F1 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
| Open filing 0001193125-26-118762 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Herriott James Officer: SVP, General Counsel Sec | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 1,762 | — | — | 0 | Indirect (I) Held in 401(k) Plan | No | F1 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
| Open filing 0001193125-26-118762 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Herriott James Officer: SVP, General Counsel Sec | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (793) — exercise price 92.62 | Disposed (D) | 793 | — | — | 0 | Direct (D) | No | F3, F2 - F3 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F2 These options became exercisable on February 26, 2023.
| Open filing 0001193125-26-118762 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Herriott James Officer: SVP, General Counsel Sec | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (2,861) — exercise price 98.18 | Disposed (D) | 2,861 | — | — | 0 | Direct (D) | No | F3, F4 - F3 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F4 These options became exercisable on February 14, 2024.
| Open filing 0001193125-26-118762 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Herriott James Officer: SVP, General Counsel Sec | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Restricted Stock Units — underlying Common Stock (20,321) | Disposed (D) | 20,321 | — | — | 0 | Direct (D) | No | F5, F7, F6 - F5 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
- F7 At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
- F6 These RSUs vest in four equal annual installments beginning on February 25, 2027.
| Open filing 0001193125-26-118762 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Zanotti Katherine S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 55,361 | — | — | 5,398 | Direct (D) | No | F1 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
| Open filing 0001193125-26-118747 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Zanotti Katherine S Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 5,398 | — | — | 0 | Direct (D) | No | F2 - F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
| Open filing 0001193125-26-118747 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Doyle James Edward Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 52,564 | — | — | 5,398 | Direct (D) | No | F1 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
| Open filing 0001193125-26-118744 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Doyle James Edward Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 5,398 | — | — | 0 | Direct (D) | No | F2 - F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
| Open filing 0001193125-26-118744 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Condella Sarah Officer: EVP, Human Resources | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 60,389 | 0 | — | 191,891 | Direct (D) | No | F1, F2 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
- F2 At the effective time of the Merger (the Effective Time), each performance based restricted stock unit (PSU) outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the Merger Consideration) in respect of each share of the Issuer's common stock, par value $0.01 per share (Common Stock) subject to such PSU, less any applicable tax withholding.
| Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Condella Sarah Officer: EVP, Human Resources | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 191,891 | — | — | 0 | Direct (D) | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Condella Sarah Officer: EVP, Human Resources | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 6,368 | — | — | 0 | Indirect (I) Held in 401(k) Plan | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Condella Sarah Officer: EVP, Human Resources | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (21,948) — exercise price 21.68 | Disposed (D) | 21,948 | — | — | 0 | Direct (D) | No | F5, F4 - F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F4 These options became exercisable in full on February 23, 2021.
| Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Condella Sarah Officer: EVP, Human Resources | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (11,700) — exercise price 44.37 | Disposed (D) | 11,700 | — | — | 0 | Direct (D) | No | F5, F6 - F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F6 These options became exercisable on February 27, 2022.
| Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Condella Sarah Officer: EVP, Human Resources | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (7,790) — exercise price 92.62 | Disposed (D) | 7,790 | — | — | 0 | Direct (D) | No | F5, F7 - F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F7 These options became exercisable on February 26, 2023.
| Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Condella Sarah Officer: EVP, Human Resources | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (6,581) — exercise price 98.18 | Disposed (D) | 6,581 | — | — | 0 | Direct (D) | No | F5, F8 - F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F8 These options became exercisable on February 14, 2024.
| Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Condella Sarah Officer: EVP, Human Resources | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Restricted Stock Units — underlying Common Stock (23,334) | Disposed (D) | 23,224 | — | — | 0 | Direct (D) | No | F9, F11, F10 - F9 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
- F11 At the Effective Time, each RSU outstanding as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
- F10 These RSUs vest in four equal annual installments beginning on February 25, 2027.
| Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Barber Michael J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 7,738 | — | — | 5,398 | Direct (D) | No | F1 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
| Open filing 0001193125-26-118742 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Barber Michael J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 5,398 | — | — | 0 | Direct (D) | No | F2 - F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
| Open filing 0001193125-26-118742 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Barber Michael J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Deferred Stock Units — underlying Common Stock (7,422) — exercise price 0 | Disposed (D) | 7,422 | 0.00 | 0 Derived: shares × price per share. Exact value 0.00. | 0 | Direct (D) | No | F3, F4 - F3 Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy (each a DSU). Each DSU represents a contingent right to receive one share of Exact Sciences Corporation common stock.
- F4 At the Effective Time, each DSU outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such DSU, less any applicable tax withholding.
| Open filing 0001193125-26-118742 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Bloomer Aaron Officer: EVP, Chief Financial Officer | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 89,911 | 0 | — | 138,679 | Direct (D) | No | F1, F2 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
- F2 At the effective time of the Merger (the Effective Time), each performance based restricted stock unit (PSU) outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the Merger Consideration) in respect of each share of the Issuer's common stock, par value $0.01 per share (Common Stock) subject to such PSU, less any applicable tax withholding.
| Open filing 0001193125-26-118759 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Bloomer Aaron Officer: EVP, Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 138,679 | — | — | 0 | Direct (D) | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118759 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Bloomer Aaron Officer: EVP, Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 417 | — | — | 0 | Indirect (I) Held in 401(k) Plan | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118759 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Bloomer Aaron Officer: EVP, Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Restricted Stock Units — underlying Common Stock (4,395) | Disposed (D) | 4,395 | — | — | 0 | Direct (D) | No | F4, F6, F5 - F4 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
- F6 At the Effective Time, each RSU granted before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding.
- F5 These RSUs vest in four equal annual installments beginning on February 27, 2026.
| Open filing 0001193125-26-118759 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Bloomer Aaron Officer: EVP, Chief Financial Officer | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Restricted Stock Units — underlying Common Stock (28,063) | Disposed (D) | 28,063 | — | — | 0 | Direct (D) | No | F4, F7, F8 - F4 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
- F7 At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
- F8 These RSUs vest in four equal annual installments beginning on February 25, 2027.
| Open filing 0001193125-26-118759 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Popovits Kimberly J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 6,725 | — | — | 9,656 | Direct (D) | No | F1 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
| Open filing 0001193125-26-118745 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Popovits Kimberly J Director | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 9,656 | — | — | 0 | Direct (D) | No | F2 - F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
| Open filing 0001193125-26-118745 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | A Grant, award or other acquisition pursuant to Rule 16b-3(d) Common Stock | Acquired (A) | 119,312 | 0 | — | 1,397,738 | Direct (D) | No | F1, F2 - F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
- F2 At the effective time of the Merger (the Effective Time), each performance based restricted stock unit (PSU) outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the Merger Consideration) in respect of each share of the Issuer's common stock, par value $0.01 per share (Common Stock) subject to such PSU, less any applicable tax withholding.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 1,397,738 | — | — | 0 | Direct (D) | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 29,061 | — | — | 0 | Indirect (I) Held in 401(k) Plan | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 46,538 | — | — | 0 | Indirect (I) Held in Grantor Retained Annuity Trust | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 86,750 | — | — | 0 | Indirect (I) Held in Grantor Retained Annuity Trust | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Common Stock | Disposed (D) | 117,427 | — | — | 0 | Indirect (I) Held in Grantor Retained Annuity Trust | No | F3 - F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (235,388) — exercise price 21.68 | Disposed (D) | 235,388 | — | — | 0 | Direct (D) | No | F5, F4 - F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F4 These options became exercisable in full on February 23, 2021.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (66,047) — exercise price 44.37 | Disposed (D) | 66,047 | — | — | 0 | Direct (D) | No | F5, F8 - F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F8 These options became exercisable on February 27, 2022.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (34,110) — exercise price 92.62 | Disposed (D) | 34,110 | — | — | 0 | Direct (D) | No | F5, F9 - F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F9 These options became exercisable on February 26, 2023.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Stock Options (Right to Buy) — underlying Common Stock (100,916) — exercise price 98.18 | Disposed (D) | 100,916 | — | — | 0 | Direct (D) | No | F5, F10 - F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
- F10 These options became exercisable on February 14, 2024.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |
| 2026-03-23 Filed 2026-03-23 | Conroy Kevin T Director · Officer: President and CEO | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) Derivative security: Restricted Stock Units — underlying Common Stock (18,143) | Disposed (D) | 18,143 | — | — | 0 | Direct (D) | No | F6, F7, F15 - F6 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
- F7 At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding.
- F15 These RSUs vest in four equal annual installments beginning on February 28, 2024.
| Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row |